New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
AIM ImmunoTech Inc. (AIM) vs Alzamend Neuro, Inc. (ALZN)
- AIM ImmunoTech Inc. AIM 0.12 −7.69%
- Alzamend Neuro, Inc. ALZN 1.02 −1.92%
AIM ImmunoTech Inc. and Alzamend Neuro, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Alzamend Neuro, Inc. are of similar size ($4.9M and $4.8M). Alzamend Neuro, Inc. has the higher net margin (0.00% vs −15,526.4%) and the higher return on invested capital (0.00% vs −5,687.5%). Across the 14 metrics below, Alzamend Neuro, Inc. leads on 11 and AIM ImmunoTech Inc. on 3.
Valuation
Profitability
| Metric | AIM | ALZN | Biotechnology median |
|---|---|---|---|
| Gross margin | 38.46% | 0.00% | 70.18% |
| Operating margin | (12,800.00%) | 0.00% | 0.00% |
| Net margin | (15,526.37%) | 0.00% | 0.00% |
| Free cash flow margin | (13,792.31%) | 0.00% | 0.00% |
| Return on equity | (2,828.63%) | (163.23%) | (51.58%) |
| Return on assets | (185.36%) | (122.36%) | (45.91%) |
| Return on invested capital | (5,687.50%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack